Dechert LLP is well-placed to advise clients engaged in major cross-border transactions, including assisting with patent strategies tied to deals. On the contentious front, the firm’s litigators represent clients in patent disputes tied to a variety of drugs, and are also well versed in handling MDLs and class actions arising out of product liability claims. Boston-based patent specialist Andrea Reid advises biotech and pharmaceutical clients on the management of their IP portfolios, offering a deep understanding of the drug discovery and development processes and leading the practice alongside New York’s David Rosenthal, who advises life sciences-focused investors on IPOs, secondary offerings and licensing matters. Also based in New York, litigator Katherine Helm handles a broad spectrum of patent-related disputes, representing both plaintiffs and defendants in infringement suits and tackling commercial issues including breach of contract and antitrust litigations.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • 'The collective discipline, first-hand knowledge of particular issues and the patience to explain complex issues is what makes the team invaluable.'

Key clients

  • 4E Therapeutics
  • AbbVie/Allergan
  • Aldeyra Therapeutics
  • argenx SE
  • Atlas Ventures
  • Bicycle Therapeutics
  • Biogen
  • Cerus Endovascular
  • Chiesi Farmaceutici S.p.A.
  • Dana-Farber Cancer Institute
  • Diffusion Pharmaceuticals
  • Eli Lilly and Company
  • Endo Pharmaceuticals
  • Forbion Capital Partners
  • GlaxoSmithKline
  • Homology Medicines
  • Ikena Oncology
  • Ipsen
  • Johnson & Johnson
  • Longwood Fund
  • Moderna Therapeutics
  • Nimbus Therapeutics
  • Sanofi SA
  • Solu Therapeutics
  • Quest Diagnostics

Work highlights

  • Advised Nimbus Therapeutics’ on patent issues relating to highly selective, allosteric TYK2 inhibitor portfolio to address multiple immune-mediated diseases.
  • Represented GSK as lead counsel in connection with multidistrict and state court litigation alleging that Zantac, a type of heartburn medication, causes cancer as a result of the formation of the chemical NDMA.
  • Advised Chiesi Farmaceutici S.p.A. in its definitive agreement to acquire Amryt Pharma Plc in an all-cash transaction valued at US$1.48bn.

Lawyers

Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.

Practice head

The lawyer(s) leading their teams.

Andrea Reid, David Rosenthal

Other key lawyers

Katherine Helm